| 001 | 131000 | ||
| 005 | 20240228143506.0 | ||
| 024 | 7 | _ | |a 10.1186/s12885-016-2388-9 |2 doi |
| 024 | 7 | _ | |a pmid:27268034 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4896000 |2 pmc |
| 024 | 7 | _ | |a altmetric:8528428 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-06076 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Marin Zapata, Paula Andrea |0 P:(DE-He78)bc2630c8bb9f2fad2ab86d7b2c7c0361 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Time course decomposition of cell heterogeneity in TFEB signaling states reveals homeostatic mechanisms restricting the magnitude and duration of TFEB responses to mTOR activity modulation. |
| 260 | _ | _ | |a London |c 2016 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1522153598_18537 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a TFEB (transcription factor EB) regulates metabolic homeostasis through its activation of lysosomal biogenesis following its nuclear translocation. TFEB activity is inhibited by mTOR phosphorylation, which signals its cytoplasmic retention. To date, the temporal relationship between alterations to mTOR activity states and changes in TFEB subcellular localization and concentration has not been sufficiently addressed.mTOR was activated by renewed addition of fully-supplemented medium, or inhibited by Torin1 or nutrient deprivation. Single-cell TFEB protein levels and subcellular localization in HeLa and MCF7 cells were measured over a time course of 15 hours by multispectral imaging cytometry. To extract single-cell level information on heterogeneous TFEB activity phenotypes, we developed a framework for identification of TFEB activity subpopulations. Through unsupervised clustering, cells were classified according to their TFEB nuclear concentration, which corresponded with downstream lysosomal responses.Bulk population results revealed that mTOR negatively regulates TFEB protein levels, concomitantly to the regulation of TFEB localization. Subpopulation analysis revealed maximal sensitivity of HeLa cells to mTOR activity stimulation, leading to inactivation of 100 % of the cell population within 0.5 hours, which contrasted with a lower sensitivity in MCF7 cells. Conversely, mTOR inhibition increased the fully active subpopulation only fractionally, and full activation of 100 % of the population required co-inhibition of mTOR and the proteasome. Importantly, mTOR inhibition activated TFEB for a limited duration of 1.5 hours, and thereafter the cell population was progressively re-inactivated, with distinct kinetics for Torin1 and nutrient deprivation treatments.TFEB protein levels and subcellular localization are under control of a short-term rheostat, which is highly responsive to negative regulation by mTOR, but under conditions of mTOR inhibition, restricts TFEB activation in a manner dependent on the proteasome. We further identify a long-term, mTOR-independent homeostatic control negatively regulating TFEB upon prolonged mTOR inhibition. These findings are of relevance for developing strategies to target TFEB activity in disease treatment. Moreover, our quantitative approach to decipher phenotype heterogeneity in imaging datasets is of general interest, as shifts between subpopulations provide a quantitative description of single cell behaviour, indicating novel regulatory behaviors and revealing differences between cell types. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Basic Helix-Loop-Helix Leucine Zipper Transcription Factors |2 NLM Chemicals |
| 650 | _ | 7 | |a TFEB protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a MTOR protein, human |0 EC 2.7.1.1 |2 NLM Chemicals |
| 650 | _ | 7 | |a TOR Serine-Threonine Kinases |0 EC 2.7.1.1 |2 NLM Chemicals |
| 700 | 1 | _ | |a Beese, Carsten Jörn |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Jünger, Anja |0 P:(DE-He78)11a50a5f1511a233224b6678f371648a |b 2 |u dkfz |
| 700 | 1 | _ | |a Dalmasso, Giovanni |0 P:(DE-He78)867c5101ca69c6cd71785e3a3b464273 |b 3 |u dkfz |
| 700 | 1 | _ | |a Brady, Nathan R |0 P:(DE-He78)5bf984e94f0a31773a103cd293e01f92 |b 4 |u dkfz |
| 700 | 1 | _ | |a Hamacher-Brady, Anne |0 P:(DE-He78)a8657988a6082d4d90605e15cd5d3302 |b 5 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1186/s12885-016-2388-9 |g Vol. 16, no. 1, p. 355 |0 PERI:(DE-600)2041352-X |n 1 |p 355 |t BMC cancer |v 16 |y 2016 |x 1471-2407 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:131000 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)bc2630c8bb9f2fad2ab86d7b2c7c0361 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)11a50a5f1511a233224b6678f371648a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)867c5101ca69c6cd71785e3a3b464273 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)5bf984e94f0a31773a103cd293e01f92 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)a8657988a6082d4d90605e15cd5d3302 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |2 G:(DE-HGF)POF3-300 |v Functional and structural genomics |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BMC CANCER : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)B190-20160331 |k B190 |l e:Bio Nachwuchsgruppe Lysosomale Systembiologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A150-20160331 |k A150 |l Systembiologie der Signaltransduktion |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)B170-20160331 |k B170 |l Systembiologie von Zelltod-Mechanismen |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B190-20160331 |
| 980 | _ | _ | |a I:(DE-He78)A150-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B170-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::